{
    "root": "34f331d6-af84-69ea-e063-6394a90ae36e",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Acyclovir",
    "value": "20250512",
    "ingredients": [
        {
            "name": "CARBOXYMETHYLCELLULOSE SODIUM",
            "code": "K679OBS311",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_85146"
        },
        {
            "name": "GLYCERIN",
            "code": "PDC6A3C0OX",
            "drugbank_id": "https://go.drugbank.com/drugs/DB09462"
        },
        {
            "name": "METHYLPARABEN",
            "code": "A2I8C7HI9T",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31835"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "PROPYLPARABEN",
            "code": "Z8IX2SC1OH",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32063"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        },
        {
            "name": "SORBITOL",
            "code": "506T60A25R",
            "drugbank_id": "https://go.drugbank.com/drugs/DB01638"
        },
        {
            "name": "ACYCLOVIR",
            "code": "X4HES1O11F",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_2453"
        }
    ],
    "indications": {
        "text": "herpes zoster infections : acyclovir indicated acute treatment herpes zoster ( shingles ) . genital herpes : acyclovir indicated treatment initial episodes management recurrent episodes genital herpes . chickenpox : acyclovir indicated treatment chickenpox ( varicella ) .",
        "doid_entities": [
            {
                "text": "herpes zoster (DOID:8536)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8536"
            },
            {
                "text": "genital herpes (DOID:8704)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8704"
            },
            {
                "text": "chickenpox (DOID:8659)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8659"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "acute treatment herpes zoster:800 mg every 4 hours orally , 5 times daily 7 10 days . genital herpes : treatment initial genital herpes : 200 mg every 4 hours , 5 times daily 10 days . chronic suppressive therapy recurrent disease : 400 mg 2 times daily 12 months , followed re-evaluation . alternative regimens included doses ranging 200 mg 3 times daily 200 mg 5 times daily . frequency severity episodes untreated genital herpes may change time . 1 year therapy , frequency severity patient \u2019 genital herpes infection re-evaluated assess need continuation therapy acyclovir . intermittent therapy : 200 mg every 4 hours , 5 times daily 5 days . therapy initiated earliest sign symptom ( prodrome ) recurrence . treatment chickenpox : children ( 2 years age older ) : 20 mg/kg per doseorally 4 times daily ( 80 mg/kg/day ) 5 days . children 40 kg receive adult dose chickenpox . adults children 40 kg : 800 mg 4 times daily 5 days . intravenous acyclovir indicated treatment varicella-zoster infections immunocompromised patients . therapy indicated , initiated earliest sign symptom chickenpox . information efficacy therapy initiated 24 hours onset signs symptoms . patients acute chronic renal impairment : patients renal impairment , dose acyclovir oral suspension modified shown table 3 : table 3 : modification renal impairment creatinine adjusted regimen normal clearance dose regimen ( ml/min/1.73m 2 ) ( mg ) dosing interval 200 mg every 4 hours > 10 200 every 4 hours , 5 x daily 0 10 200 every 12 hours 400 mg every 12 hours > 10 400 every 12 hours 0 10 200 every 12 hours 800 mg every 4 hours > 25 800 every 4 hours , 5 x daily 10 25 800 every 8 hours 0 10 800 every 12 hours hemodialysis : patients require hemodialysis , mean plasma half-life acyclovir hemodialysis approximately 5 hours . results 60 % decrease plasma concentrations following 6-hour dialysis period . therefore , patient \u2019 dosing schedule adjusted additional dose administered dialysis . peritoneal dialysis : supplemental dose appears necessary adjustment dosing interval . bioequivalence forms : acyclovir oral suspension shown bioequivalent acyclovir capsules ( n = 20 ) 1 acyclovir 800-mg tablet shown bioequivalent 4 acyclovir 200-mg capsules ( n = 24 ) .",
        "doid_entities": [
            {
                "text": "herpes zoster (DOID:8536)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8536"
            },
            {
                "text": "genital herpes (DOID:8704)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8704"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "chickenpox (DOID:8659)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8659"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "acute chronic renal",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_98255"
            }
        ]
    },
    "warningsAndPrecautions": "acyclovir oral suspension , usp ( off-white , banana-flavored ) containing 200 mg acyclovir teaspoonful ( 5 ml ) . ndc 17856-0083-01 acyclovir oral suspension , usp 200 mg/5 ml ndc 17856-0083-02 acyclovir oral suspension , usp 400 mg/10 ml store 15\u00b0 25\u00b0c ( 59\u00b0 77\u00b0f ) . protect light . dispense tight container defined usp . distributed : atlantic biologicals corp. miami , fl 33179",
    "adverseReactions": "acyclovir oral suspension contraindicated patients develop hypersensitivity acyclovir valacyclovir .",
    "indications_original": "Herpes Zoster Infections:Acyclovir is indicated for the acute treatment of herpes zoster (shingles).\n\n \n                  \n                     Genital Herpes:Acyclovir is indicated for the treatment of initial episodes and the management of recurrent episodes of genital herpes.\n\n \n                  \n                     Chickenpox:Acyclovir is indicated for the treatment of chickenpox (varicella).",
    "contraindications_original": "Acute Treatment of Herpes Zoster:800 mg every 4 hours orally, 5 times daily for 7 to 10 days.\n\n \n                  \n                     Genital Herpes:Treatment of Initial Genital Herpes: 200 mg every 4 hours, 5 times daily for 10 days.\n\n \n                  \n                     \n                        Chronic Suppressive Therapy for Recurrent Disease:\n                     400 mg 2 times daily for up to 12 months, followed by re-evaluation. Alternative regimens have included doses ranging from 200 mg 3 times daily to 200 mg 5 times daily.\n\n \n                  The frequency and severity of episodes of untreated genital herpes may change over time. After 1 year of therapy, the frequency and severity of the patient\u2019s genital herpes infection should be re-evaluated to assess the need for continuation of therapy with acyclovir.\n                  \n                     \n                        Intermittent Therapy:\n                     200 mg every 4 hours, 5 times daily for 5 days. Therapy should be initiated at the earliest sign or symptom (prodrome) of recurrence.\n\n \n                  \n                     Treatment of Chickenpox:\n                     \n                        Children (2 Years of Age and Older):\n                     20 mg/kg\n \n  per doseorally 4 times daily (80 mg/kg/day) for 5 days. Children over 40 kg should receive the adult dose for chickenpox.\n\n \n                  Adults and Children Over 40 kg: 800 mg 4 times daily for 5 days.\n                  Intravenous acyclovir is indicated for the treatment of varicella-zoster infections in immunocompromised patients.\n                  When therapy is indicated, it should be initiated at the earliest sign or symptom of chickenpox. There is no information about the efficacy of therapy initiated more than 24 hours after onset of signs and symptoms.\n                  \n                     Patients with Acute or Chronic Renal Impairment:In patients with renal impairment, the dose of acyclovir oral suspension should be modified as shown in Table 3:\n\n \n                  \n                     Table 3: Dosage Modification for Renal Impairment\n                     \n                     \n                     \n                     \n                     \n                        \n                           \n                           \u00a0 Creatinine\n                           \u00a0 Adjusted Dosage Regimen\n                        \n                        \n                           \u00a0 Normal\n                           \u00a0 Clearance\n                           \u00a0 Dose\n                           \n                        \n                        \n                           \u00a0 Dosage Regimen\n                           \u00a0 (mL/min/1.73m\n    \n     2)\n   \n    \n                           \u00a0 (mg)\n                           \u00a0 Dosing Interval\n                        \n                        \n                           \u00a0200 mg every 4 hours\n                           \u00a0>10\n                           \u00a0200\n                           \u00a0every 4 hours, 5 x daily\n                        \n                        \n                           \n                           \u00a00 to 10\n                           \u00a0200\n                           \u00a0every 12 hours\n                        \n                        \n                           \u00a0400 mg every 12 hours\n                           \u00a0>10\n                           \u00a0400\n                           \u00a0every 12 hours\n                        \n                        \n                           \n                           \u00a00 to 10\n                           \u00a0200\n                           \u00a0every 12 hours\n                        \n                        \n                           \u00a0800 mg every 4 hours\n                           \u00a0>25\n                           \u00a0800\n                           \u00a0every 4 hours, 5 x daily\n                        \n                        \n                           \n                           \u00a010 to 25\n                           \u00a0800\n                           \u00a0every 8 hours\n                        \n                        \n                           \n                           \u00a00 to 10\n                           \u00a0800\n                           \u00a0every 12 hours\n                        \n                     \n                  \n                  \n                     Hemodialysis:For patients who require hemodialysis, the mean plasma half-life of acyclovir during hemodialysis is approximately 5 hours. This results in a 60% decrease in plasma concentrations following a 6-hour dialysis period. Therefore, the patient\u2019s dosing schedule should be adjusted so that an additional dose is administered after each dialysis.\n\n \n                  \n                     Peritoneal Dialysis:No supplemental dose appears to be necessary after adjustment of the dosing interval.\n\n \n                  \n                     Bioequivalence of Dosage Forms:Acyclovir oral suspension was shown to be bioequivalent to acyclovir capsules (n = 20) and 1 acyclovir 800-mg tablet was shown to be bioequivalent to 4 acyclovir 200-mg capsules (n = 24).",
    "warningsAndPrecautions_original": "Acyclovir oral suspension, USP (off-white, banana-flavored) containing 200 mg acyclovir in each teaspoonful (5 mL).\n                  NDC 17856-0083-01\u00a0\u00a0Acyclovir Oral Suspension, USP\u00a0\u00a0200 mg/5 mL\n                  NDC 17856-0083-02\u00a0\u00a0Acyclovir Oral Suspension, USP\u00a0 400 mg/10 mL\n                  \n                     Store between 15\u00b0 to 25\u00b0C (59\u00b0 to 77\u00b0F). Protect from light.\n                  \n                  Dispense in a tight container as defined in the USP.\n                  \n                  \n                     Distributed by:\n                  \n                  \n                     ATLANTIC BIOLOGICALS CORP.\n                  \n                  \n                     MIAMI, FL 33179",
    "adverseReactions_original": "Acyclovir oral suspension is contraindicated for patients who develop hypersensitivity to acyclovir or valacyclovir.",
    "drug": [
        {
            "name": "Acyclovir",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_2453"
        }
    ]
}